Xencor Inc (XNCR) Major Shareholder Sells $1,093,534.96 in Stock

Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III sold 26,888 shares of the stock in a transaction on Monday, July 16th. The stock was sold at an average price of $40.67, for a total transaction of $1,093,534.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

John S. Stafford III also recently made the following trade(s):

  • On Tuesday, July 10th, John S. Stafford III sold 50,293 shares of Xencor stock. The stock was sold at an average price of $39.89, for a total transaction of $2,006,187.77.
  • On Thursday, July 12th, John S. Stafford III sold 138,300 shares of Xencor stock. The stock was sold at an average price of $39.69, for a total transaction of $5,489,127.00.

Xencor opened at $42.31 on Friday, according to Marketbeat. The firm has a market cap of $2.32 billion, a P/E ratio of -40.30 and a beta of 1.64. Xencor Inc has a fifty-two week low of $18.97 and a fifty-two week high of $43.39.

Xencor (NASDAQ:XNCR) last posted its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.16). Xencor had a negative net margin of 137.35% and a negative return on equity of 18.07%. equities analysts predict that Xencor Inc will post -2.33 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of XNCR. Teacher Retirement System of Texas purchased a new position in Xencor during the fourth quarter valued at $291,000. UBS Asset Management Americas Inc. purchased a new position in Xencor during the fourth quarter valued at $205,000. Geode Capital Management LLC grew its stake in Xencor by 5.9% during the fourth quarter. Geode Capital Management LLC now owns 352,526 shares of the biopharmaceutical company’s stock valued at $7,727,000 after acquiring an additional 19,706 shares in the last quarter. Renaissance Technologies LLC grew its stake in Xencor by 56.6% during the fourth quarter. Renaissance Technologies LLC now owns 156,000 shares of the biopharmaceutical company’s stock valued at $3,420,000 after acquiring an additional 56,400 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in Xencor by 3.6% during the fourth quarter. Franklin Resources Inc. now owns 538,632 shares of the biopharmaceutical company’s stock valued at $11,807,000 after acquiring an additional 18,900 shares in the last quarter. 79.55% of the stock is owned by institutional investors.

XNCR has been the subject of a number of analyst reports. BTIG Research initiated coverage on shares of Xencor in a research note on Thursday, June 7th. They issued a “buy” rating and a $56.00 price objective for the company. Zacks Investment Research raised shares of Xencor from a “hold” rating to a “strong-buy” rating and set a $34.00 target price for the company in a research note on Saturday, May 5th. Nomura cut their target price on shares of Xencor to $28.00 and set a “neutral” rating for the company in a research note on Thursday, April 5th. ValuEngine raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 22nd. Finally, BidaskClub cut shares of Xencor from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 30th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Xencor has an average rating of “Buy” and a consensus price target of $37.88.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

See Also: What are CEFs?

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit